Cadrenal Therapeutics, INC. 8-K Filing

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share CVKD The Nasdaq Stock Mar
• $1,770,028 — program for the offer and sale of up to $1,770,028 of shares of the Company's common stock
• $10,005,300 — f, the Company has sold an aggregate of $10,005,300 of shares of Common Stock pursuant to t

Filing Documents

• ea0270908-8k_cadrenal.htm (8-K) — 32KB
• ea027090801ex5-1_cadrenal.htm (EX-5.1) — 11KB
• ex5-1_001.jpg (GRAPHIC) — 2KB
• 0001213900-25-125433.txt ( ) — 213KB
• cvkd-20251223.xsd (EX-101.SCH) — 3KB
• cvkd-20251223_lab.xml (EX-101.LAB) — 33KB
• cvkd-20251223_pre.xml (EX-101.PRE) — 22KB
• ea0270908-8k_cadrenal_htm.xml (XML) — 3KB

01. Other Events

Item 8.01. Other Events. On December 23, 2025, Cadrenal Therapeutics, Inc., a Delaware corporation, (the "Company"), filed a prospectus supplement (the "Prospectus Supplement") with the U.S. Securities and Exchange Commission (the "SEC") in connection with the Company's "at the market offering" program for the offer and sale of up to $1,770,028 of shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), from time to time through H.C. Wainwright & Co., LLC ("Wainwright"), as sales agent, pursuant to the Company's existing At the Market Offering Agreement (the "ATM Agreement"), dated March 11, 2024. As of the date hereof, the Company has sold an aggregate of $10,005,300 of shares of Common Stock pursuant to the ATM Agreement. The offer and sale of up to $1,770,028 shares of Common Stock by the Company under the ATM Agreement is made pursuant to the Company's registration statement on Form S-3 (File No. 333-277835), initially filed with the SEC on March 12, 2024 and declared effective by the SEC on March 20, 2024 (the "Registration Statement"), and the Prospectus Supplement. Under the ATM Agreement, the Company will set the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. Subject to the terms and conditions of the ATM Agreement, Wainwright may sell the shares by methods deemed to be an "at the market offering" as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. Wainwright will use commercially reasonable efforts in conducting such sales activities consistent with its normal trading and sales practices, and applicable state and federal laws. The ATM Agreement may be terminated by the Company upon written notice to Wainwright, as specified in the ATM Agreement for any reason or by Wa

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are furnished with this Current Report on Form 8-K: Exhibit Number Exhibit Description 1.1 At the Market Offering Agreement by and between Cadrenal Therapeutics, Inc. and H.C. Wainwright & Co., LLC (incorporated by reference as Exhibit 1.1 to the Current Report on Form 8-K filed on March 12, 2024) 5.1 Opinion of Blank Rome LLP 23.1 Consent of Blank Rome LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within in the inline XBRL document) 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 23, 2025 CADRENAL THERAPEUTICS, INC. By: /s/ Quang X. Pham Name: Quang X. Pham Title: Chairman and Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR